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Clinical research has indicated that the use of nucleoside
reverse transcriptase inhibitor (NRTI) and HIV protease
inhibitor (PI) therapy is associated with a risk of long-
term toxicity syndromes, and that the aetiopathogenesis
of these adverse effects is independent of the antiretro-
viral effects of these drugs. In relation to the
lipodystrophy syndrome, it appears that the most
powerful determinant of subcutaneous fat wasting is an
interaction between these two drug classes. In this
review, possible mechanisms underlying the contribu-
tions of both PI and NRTI drugs are reviewed, with an
emphasis on their effects on adipose tissue. On this basis,
an ‘adipocentric’, or minimal model of the syndrome is
developed, in which divergent effects at the adipocyte of
NRTIs (mitochondrial toxicity) and PIs (insulin resistance
and impaired adipocyte maturation) interact to produce a
phenotype that is consistent with clinical observations.
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Clinical studies, whether based on observational
cohorts or clinical trials, have contributed significantly
to an increased understanding of the lipodystrophy
syndrome that accompanies long-term use of antiretro-
viral therapy [1]. Taken together, they provide a
conceptual framework that can inform basic science
research, with the ultimate aim of gaining an under-
standing of the underlying aetiopathogenesis of the
syndrome at the molecular level. The elucidation of
these mechanisms should then be able to guide the
selection of antiretroviral therapy combinations less
likely to induce long-term complications, as well as
provide a rational basis for the clinical management of
individuals with established lipodystrophy.
An analysis of the available clinical data was the
subject of a previous review [1], and will be briefly reit-
erated. This review also addressed methodological
issues relating to the clinical evaluation and definition
of the lipodystrophy syndrome. Of particular impor-
tance is the recognition that component clinical
features of the syndrome (body composition changes,
such as subcutaneous fat wasting and/or visceral or
localized fat accumulation; and metabolic abnormali-
ties such as insulin resistance and dyslipidaemia) need
to be analysed separately, so that their relation to each
other, as well as to interventions, such as introduction
or cessation of antiretroviral drugs, can be objectively
assessed.
Initial aetiopathogenic models of the lipodystrophy
syndrome focused primarily on the role of HIV
protease inhibitors (PIs), as the introduction of this
class of drug into clinical practice was temporally asso-
ciated with the first descriptions of the syndrome. It
has since become apparent that subcutaneous fat
wasting, in particular, can also occur in patients
receiving only nucleoside reverse transcriptase
inhibitors (NRTIs) [2,3], and that NRTIs contribute to
lipodystrophic changes in body composition when
both drug classes are used in combination [4]. PI use
appears to be more strongly associated with the ‘meta-
bolic’ component of the syndrome, characterized by
increased levels of triglyceride, triglyceride-rich
lipoproteins and insulin resistance, based on the obser-
vation that these metabolic changes have been
observed after short-term exposure to PIs in healthy
volunteers [5,6], and following introduction of PI
therapy in HIV-infected patients in the absence of
changes in body composition [7,8]. NRTIs, on the
other hand, while contributing to the risk of devel-
oping peripheral fat wasting [2–4], appear to have
relatively less effect on lipid metabolism and insulin
sensitivity [1].
Assessing the effects of specific drugs within these
two drug classes, there is no current evidence that
choice of PI significantly affects the incidence or
severity of morphological [9] or metabolic [10] compo-
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exception that ritonavir therapy is associated with
higher triglyceride levels [10,11]. Within the NRTI
class there is evidence from observational studies, as
well as randomized clinical trials, that stavudine
therapy is associated with an increased relative risk
(approximately twofold) of peripheral fat wasting
compared with zidovudine [2–4,9,12–14].
An important concept that has recently emerged is
that when NRTIs and PIs are combined in highly active
antiretroviral therapy (HAART) regimens, it is the
interaction of these drug classes that is the most
powerful predictor of lipodystrophic body composi-
tion changes, with a significant (>5-fold) increase in
relative risk compared with the use of one drug class.
This observation has now been made in clinical trials,
in which NRTI therapy is introduced to pre-existing
dual PI regimens [15–18] as well as in the more
familiar comparison of dual NRTI regimens versus PI-
containing HAART [4] (Figure 1). The magnitude of
this interaction effect in clinical studies is far greater
than observed differences in immunological or virolog-
ical response to dual therapy regimens (either PI- or
NRTI-based) [4,15–18] compared with combination
HAART, indicating that the interaction between these
drug classes is not mediated by a non-specific effect on
immune restoration. This is probably best exemplified
in the Prometheus study, in which the addition of
stavudine to stable long-term ritonavir/saquinavir
therapy had no significant effect on virological or
immunological response [16], while the relative risk of
developing clinically apparent changes in body compo-
sition increased ~fivefold [15]. This is also true for
differences within the NRTI class, where equivalent
anti-HIV efficacy but divergent effects on lipodys-
trophy have been shown in comparisons of zidovudine
and stavudine therapy [2–4,12].
In this review we propose to further examine the
effects of PI and NRTI therapy that may be relevant to
the aetiopathogenesis of the lipodystrophy syndrome,
and to explore how these effects may interact at the
molecular/cellular level to produce the lipodystrophy
phenotype. We propose a ‘minimal model’ of lipodys-
trophy pathogenesis that focuses on adipose-specific
effects, and accounts for the clinical observations, in
an attempt to provide a theoretical framework for
further research. Undoubtedly this model will require
modification in light of the results of future studies, as
knowledge of the underlying mechanisms is refined.
The contribution of NRTIs to lipodystrophy
The lipodystrophy phenotype that is observed in PI-
naive NRTI-treated individuals differs in some
respects to that seen in association with PI treatment.
Subcutaneous fat wasting appears to be a dominant
manifestation [19], and although mild increases in
visceral adiposity have been observed in clinical
studies [2,9], the magnitude of this effect is far less
than that observed in PI-treated patients [9,20], and
does not appear to be influenced by choice of NRTI
[9,12].
D Nolan et al.
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Figure 1. Nucleoside reverse transcriptase inhibitors and protease inhibitors interact to cause fat wasting in highly active
antiretroviral therapy-associated lipodystrophy
Combining the results of the Prometheus study* and the Western Australian HIV Cohort Study† demonstrates the interactive effect on fat wasting of combining
nucleoside reverse transcriptase inhibitors and protease inhibitor therapy, compared with dual nucleoside reverse transcriptase inhibitors or dual protease inhibitor
regimens. NRTI, nucleoside reverse transcriptase inhibitor; RTV, ritonavir; SQV, saquinavir; d4T, stavudine; LD, lipodystrophy.In terms of the metabolic component of the
syndrome, studies by Saint-Marc [2] and Galli et al.
[21] have demonstrated mildly elevated levels of
triglycerides and decreased HDL cholesterol in stavu-
dine-treated patients. Risk of developing these
metabolic alterations was not found to be associated
with body composition changes [21], suggesting that
NRTIs may have an independent effect on some
aspects of lipid metabolism. However, the addition of
stavudine to dual PI regimens produced no incremental
rise in triglyceride or cholesterol levels, suggesting that
these lipid changes have minor clinical significance in
the presence of PI therapy [22]. Similarly, NRTI-asso-
ciated lipodystrophy, and peripheral fat wasting in the
absence of visceral fat accumulation in general (‘pure
lipoatrophy’), is not associated with significant hyper-
insulinaemia, insulin resistance, or the dyslipidaemic
profile that accompanies insulin resistance (that is,
elevated apolipoprotein B and VLDL cholesterol in
addition to elevated triglyceride and decreased HDL-
cholesterol levels) [2,9,23].
A study of in vivo lipid metabolism by Ware et al.
has demonstrated an increased retention time of
dietary lipid within the circulation as free fatty acid in
PI-naive patients with lipodystrophy [24]. The authors
suggested the existence of an NRTI-induced defect in
cellular uptake of fatty acids, and proposed a mecha-
nism involving the inhibition of fatty acid-binding
proteins (FABPs) that are responsible for fatty acid
uptake and intracellular trafficking [24]. Consistent
with this hypothesis, FABP mRNA levels were found to
be decreased in stavudine-treated mice [25]. Given the
postulated association between NRTIs and mitochon-
drial toxicity, it is interesting to note that FABPs are
derived from a mitochondrial precursor (mitochon-
drial aspartate aminotransferase), which requires
intramitochondrial activation before being secreted
into the cytosol [26,27].
Mechanisms of NRTI-mediated toxicity:
mitochondrial toxicity and the ‘pol-γ ’
hypothesis
NRTIs act as false substrates for the polymerase
activity of HIV reverse transcriptase, and are charac-
terized by the lack of a hydroxyl group in the 3′
position. Thus, when the activated triphosphate form
of these compounds are used by a viral (or host) poly-
merase and added to a nascent DNA chain, there is no
site of attachment for the next nucleotide, terminating
DNA synthesis at that position. While the major poly-
merase involved in nuclear DNA synthesis
(polymerase-α ) is able to discriminate effectively
against these nucleoside analogues, this ability is not
shared by the sole polymerase present in mitochondria,
polymerase-γ [28]. This polymerase performs a
number of critical functions, as mitochondria within a
cell (of which there may be hundreds) contain multiple
copies of their own (extrachromosomal) mitochon-
drial genome. The maintenance of bioenergetic
function in all metabolically active cells therefore
requires ongoing polymerase-γ -mediated mitochon-
drial (mt) DNA synthesis as well as repair (even in
post-mitotic cells, in which nuclear DNA synthesis is
negligible), creating an ongoing requirement for nucle-
oside uptake and use by mitochondria. It is perhaps
not surprising, therefore, that chronic toxicities
induced by NRTI compounds appear to be the conse-
quences of mitochondrial dysfunction.
The possible link between polymerase-γ inhibition
and lipodystrophy was first presented by Brinkman in
1999 [29], and this area has since been reviewed by
Kakuda [30] and White [31], in which the syndrome
is considered in the context of other NRTI-induced
toxicities. The basic premise of the ‘pol-γ ’ hypothesis
is that NRTI-induced inhibition of polymerase-γ leads
to depletion of cellular mtDNA content through inhi-
bition of mtDNA synthesis. Toxicity at the cellular
and tissue level is the consequence of loss of mito-
chondrial bioenergetic function, once mtDNA levels
have fallen beyond a critical level where the produc-
tion of mtDNA-encoded protein subunits of the
mitochondrial respiratory chain [13], and RNAs (22
tRNAs and 2 rRNAs) is insufficient to meet the cell’s
energy requirements.
There is an increasing understanding of the impor-
tance of mitochondrial partitioning of these drugs
(that is, their ability to enter the mitochondrial
compartment within the cell cytosol) in determining
toxicity [32], particularly following the important
discovery of a mitochondrial inner membrane trans-
porter that is able to facilitate the entry of NRTI
triphosphate derivatives into mitochondria [33].
Based on these considerations, a modified version of
the ‘pol-γ ’ hypothesis is proposed (modifications in
italics): (1) the NRTI has the pharmacodynamic capa-
bility to enter the target cells, and subsequently to
enter the mitochondrion in either its free-drug or
phosphorylated form; (2) the target cell possesses acti-
vated cellular nucleoside kinases to mono-, di- and
subsequently triphosphorylate the NRTI, so that the
active triphosphate form of the drug is present within
the mitochondrion; (3) the triphosphorylated NRTI
can inhibit DNA polymerase-γ either by serving as a
competitive (ineffective) alternative substrate or by
chain termination of the nascent mtDNA strand (non-
competitive); (4) the target tissue has a metabolic
reliance on the maintenance of 
mitochondrial function (rather than ‘oxidative phos-
phorylation’).
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thymidine analogues) may be considered in this light,
as NRTIs of interest in relation to the lipodystrophy
syndrome (Figure 2). Structurally, the two drugs are
similar, with the important difference being desatura-
tion of the 2′ and 3′ positions of the sugar in stavudine,
and the presence of an azide group in zidovudine. Both
compounds are hydrophilic, with relatively short
plasma half-lives (1–1.5 h) [34], and thus have no
redistribution phase to adipose tissue. At the cellular
level, zidovudine and stavudine enter the cell by passive
diffusion and are then sequentially phosporylated to
mono-, di-, and finally to the active triphosphate deriv-
ative. This process involves, in turn, thymidine kinase
(TK), thymidylate kinase and pyrimidine diphosphate
kinase [35]. At the subcellular level, however, there is
evidence that these compounds differ in their ability to
enter the mitochondrial compartment, and subse-
quently to inhibit mtDNA synthesis (Figure 2).
In the thymidine activation pathway, partitioning
into cytosolic and mitochondrial compartments occurs
at two stages. TK has a cytosolic form (TK1), which is
active only in S phase of mitosis, and a mitochondrial
form (TK2), which is expressed in proportion to the
mitochondrial content of the cell and is not cell-cycle
regulated [36]. It is likely that thymidine as well as the
free-drug forms of stavudine and zidovudine are able
to cross the mitochondrial double membrane without
requiring a specific carrier [37]. The rate limiting step
for activation of zidovudine is the conversion from
zidovudine-monophosphate (MP) to zidovudine-
diphosphate (DP) by thymidylate kinase (decreased
Vmax) [38]. Subsequently, low levels of zidovudine-
triphosphate (TP) limits access to the mitochondrion
via a specific deoxynucleotide carrier [33]. Zidovudine
is a relatively weak inhibitor of polymerase-γ (Ki 1–10
µM), and since steady-state whole-cell concentration of
zidovudine-TP is <0.5 µM, this suggests that zidovu-
dine at pharmacological doses fulfils the ‘pol-γ ’
hypothesis criteria only mildly.
Stavudine may be able to enter the mitochondrion in
its free-drug form, or in its TP form via the deoxynu-
cleotide carrier. It has a relatively high affinity for
polymerase-γ (<0.1 µM), and on this basis it could be
predicted that pharmacological doses of stavudine
have the potential to lead to inhibit polymerase-γ ,
particularly in post-mitotic cells in which TK1 is inac-
tive.
At present it is difficult to reconcile the available
data regarding the important issue of intracellular (and
intramitochondrial) activation of stavudine. As shown
in Figure 2, it is clear that thymidine kinase-mediated
phosphorylation of free stavudine is the rate-limiting
step of stavudine phosphorylation, and that affinity of
this drug for TK1 is low [39]. In relation to affinity for
TK2, activity in the presence of stavudine was shown
D Nolan et al.
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Figure 2. Mitochondrial partitioning of zidovudine and stavudine
ZDV, zidovudine; d4T, stavudine; MP, monophosphate; DP, diphosphate; TP, triphosphate; IM, inner membrane; dNT, deoxynucleotide; TK, thymidine kinase.to be 0.005% of that observed with an equivalent
concentration of thymidine (20 µM) by Munch-
Peteresen  et al., and this has been confirmed more
recently with recombinant TK2 [36,40]. This result is
surprising, given that stavudine retains anti-HIV
activity within the pharmacological dose range in TK1-
deficient cells (IC50 HIV 0.27 µM with TK, 2.5µM in
TK-deficient CEM cells) [41], and has shown efficient
phosphorylation to the active stavudine-TP form
within isolated mitochondria [42].
This discordance may relate to the fact that the TK2
gene shows multiple transcripts, and several forms of
TK2 mRNA may also be derived from alternative
splicing or by the addition of a 3′ polyadenylation
signal [36]. It is possible, therefore, that experiments to
date have not used the TK2 specific for stavudine.
Another explanation is that stavudine may act as
substrate for another mitochondrial kinase, but this
appears less likely. The other human deoxynucleoside
kinases, deoxycytidine kinase (dCK) and deoxyguano-
sine kinase (dGK), show extensive sequence identity to
TK2 and are closely related and separate from TK1
[40]. However, dCK is cytosol-specific, while mito-
chondrial dGK is unable to recognize thymine as a
base, because of the presence of a phenylalanine
residue (Phe-156) at a critical site for thymine recogni-
tion, where thymidine kinases use a tyrosine (Tyr-172)
[43].
NRTIs and lipodystrophy
Depletion of mtDNA has now been demonstrated in
subcutaneous fat samples taken from individuals with
lipodystrophy by three independent groups [44–46]
(summarized in Table 1), providing important in vivo
data of the effects of NRTIs in the putative target
tissue. Analysis of the ultrastructure of adipocytes has
also demonstrated abnormal mitochondrial forms
(whorled cristae, elongated and branched forms) as
well as a striking increase in mitochondrial organellar
size and number [44,47,48] (Figure 3). A correlation
been mitochondrial DNA depletion and increased
mitochondrial mass has been shown in one study [46],
consistent with genetically-determined mtDNA deple-
tion syndromes, in which proliferation of
mitochondria appears to represent a compensatory
response directed by the nuclear genome [49]. This
may lead to a ‘vicious cycle’ in which increasing levels
Antiviral Therapy 6:3 149
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Table 1. Evidence of mitochondrial DNA depletion in subcutaneous fat samples from individuals with highly active antiretroviral
therapy-associated lipodystrophy
Researchers Methods Findings
Walker et al. (Germany) [44] 32 samples: 11 with LD, 12 HIV positive,  No difference in mtDNA content between
ART positive with no LD, 8 HIV HIV-negative controls and HIV positive 
negative controls, 1 HIV positive, ART naive patients treated with NNRTI+PI (n=4)
Southern blot analysis NRTI treatment associated with ↓ mtDNA 
(P=0.009)
Among ART-treated, 38% average ↓ mtDNA 
content in patients with LD compared with LD-
negative (P=0.04)
Shikuma et al. (Hawaii) [45] 69 samples from 24 individuals (8 with LD) 14/23 (61%) with LD had reduced/absent 
mtDNA, compared with 6/20 (30%) of non-LD 
controls (P=0.04), and 3/20 (15%) of HIV-
negative controls (P=0.008)
Semiquantitative assay with size fractionation of PCR  No large mtDNA mutations
product on agarose gel
Mallal et al. (Australia) [46] 17 samples: 5 with LD, 5 HIV positive, ART positive with No difference in mtDNA content between HIV-
no LD, 3 HIV positive ART-naive, 4 HIV negative controls negative and HIV positive controls
Real-time PCR-based quantitative assay MtDNA depletion associated with NRTI treat
ment (P <0.001). Within ARTpositive group,
mtDNA  depletion associated with LD (P=0.05, versus 
non-LD)
Biorad microplate assay of mt protein content Average mtDNA content compared with 
controls: LD-positive 15%, LD-negative 58% 
(adjusted for mt protein mass)
LD, lipodystrophy; mt, mitochondrial; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non- nucleoside reverse transcriptase inhibitors; PI, protease inhibitor;
ART, antiretroviral treatment.of TK2 (expressed in proportion to mitochondrial
mass) allow the further accumulation of intramito-
chondrial NRTI derivatives. This ‘proliferative’
response may also exacerbate the pathological effects
of mtDNA depletion, by further decreasing mtDNA
content relative to the mitochondrial mass and activity
that this genome must support. In this context, a study
in which cellular mtDNA content was adjusted for
mitochondrial mass (measured by mitochondrial
protein content) has shown ~85% average depletion of
mitochondrial DNA content in samples from individ-
uals with lipodystrophy, compared with controls [46];
a level of depletion that would be considered sufficient
to cause mitochondrial dysfunction. It is, however,
difficult to ascribe a ‘cut-off point’ at which the magni-
tude of mtDNA depletion is considered pathological,
particularly because assays of mitochondrial depletion
provide an ‘average’ measure of mtDNA in a tissue
sample. Hence, the extent of mtDNA depletion in indi-
vidual cells may have been underestimated, given that
cells within a tissue are heterogeneous in terms of
mtDNA content and bioenergetic status. This concept
has been referred to as the ‘bioenergetic mosaic’ theory
[50].
This underlines the importance of assessing the
functional consequences of mtDNA depletion (for
example, affects on mitochondrial respiratory activity)
in vivo, so that proximal effects of polymerase-γ inhi-
bition on the mitochondrial genome (decreased
mtDNA synthesis and repair) can be related to cellular
pathophysiology.
The consequences of mtDNA depletion and associ-
ated mitochondrial dysfunction have traditionally been
considered in terms of the affect on oxidative phos-
phorylation [29]. Adipose tissue, however, has a low
oxidative capacity in keeping with its role as an energy
substrate store [51]. The role of mitochondria in
adipocytes appears to be more complex and is directed
towards providing energy for triglyceride synthesis and
storage (Figure 4). Experimentally-induced mitochon-
drial dysfunction in adipocytes increases basal glucose
uptake, without influencing insulin-stimulated glucose
uptake [52]. While glycolysis is increased, however,
loss of mitochondrial membrane potential in
adipocytes correlates with a diversion from energy
storage (triglyceride synthesis and de novo fatty acid
synthesis) to energy use associated with increased
lactate production [53]. This is consistent with a body
of work suggesting that there are a number of cellular
mechanisms that are used to ‘sense’ the energy and fuel
status of the cell (and hence of the mitochondria)
[54–57]. In lipogenic tissues, such as adipose and liver,
a decrease in the cytosolic ATP/ADP ratio activates a
protein kinase system (AMP-activated kinase) that
diverts resources away from energy-consuming biosyn-
thetic reactions, such as triglyceride synthesis (thus
providing a fuel store that can be called on by other
cells), towards oxidative reactions that provide energy
for the ATP-depleted cell. In adipocytes, activation of
this response decreases both lipogenesis and lipolysis
[56,57].
Returning to the potential role of FABPs, there is an
adipose-specific form (A-FABP, also known as aP2 or
ALBP) whose activation is dependent on the mainte-
nance of the mitochondrial membrane potential [58]. It
D Nolan et al.
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(a) Mitochondrial proliferation with elongated mitochondrial forms within an
expanded cytoplasm is demonstrated. Redundant folds of basal lamina (arrows)
indicate loss of cellular volume, consistent with a reduction in the size of the
major intracellular triglyceride droplet. (b) Intracytoplasmic lipid droplets
(arrows) are frequent, suggestive of mobilization of triglyceride stores for lipol-
ysis and/or oxidation. These changes are also seen in ‘converted adipocytes’ in
β 3-adrenoceptor-agonist treated rats. Mitochondrial proliferation is also
evident.
Figure 3. Ultrastructural changes in subcutaneous fat
affected by highly active antiretroviral therapy-associated
lipodystrophy
(a)
(b)plays a critical role in intracellular fatty acid traf-
ficking, increasing the Vmax of free fatty acid uptake by
adipocytes [59] and directing fatty acids to nuclear
transcription factors involved in regulating lipogenesis
[60]. Through an interaction with hormone-sensitive
lipase, A-FABP also appears to direct fatty acid export
from the cell, so that liberated fatty acid may be
released rather than be made available for re-esterifica-
tion within the adipocyte [61]. While other FABPs are
likely to be involved in fatty acid uptake it may be that
there is less redundancy in relation to fatty acid export,
as A-FABP-null mice exhibit reduced lipolysis and
accumulate fatty acid intracellularly [62]. Decreased
mitochondrial activation of A-FABP, therefore, would
be predicted to reduce the efficiency of fatty acid
uptake as well as export (in keeping with the other
cellular responses to ATP depletion).
Chronic sub-lethal mitochondrial dysfunction
induced by NRTIs in adipose tissue may therefore lead
to increased glucose uptake, glycolysis and lactate
production, as well as to the accumulation of intracel-
lular fatty acids, which are directed towards oxidative
rather than biosynthetic pathways. Severe mitochon-
drial dysfunction would be predicted to produce cell
death through apoptosis following loss of bioenergetic
viability [28], while milder mitochondrial injury may
produce an adipocyte phenotype with reduced capacity
for triglyceride synthesis or fatty acid export, thus
‘isolating’ it from the metabolic demands of the body
as a whole. This would be consistent with the clinical
phenotype of NRTI-associated lipodystrophy, in which
loss of subcutaneous adipose mass is not accompanied
by insulin resistance or elevated apolipoprotein-B or
VLDL-cholesterol (both markers of increased fatty
acid delivery to the liver), or with the induction of
increased visceral adiposity. A reduction in Vmax of
adipocyte fatty acid uptake may contribute to slower
extraction of fatty acid form the circulation, and there-
fore to increased opportunity for lipid exchange
between triglyceride and HDL-cholesterol resulting in
elevated triglyceride, and reduced HDL-cholesterol,
levels.
In this context, it is interesting to note that two
recent large studies have shown that in patients
receiving PI-containing HAART, those who develop
peripheral fat wasting without increased visceral fat
accumulation (‘pure lipoatrophy’), triglyceride levels
are higher and insulin sensitivity is preserved compared
with those who develop a mixed syndrome in which
visceral fat accumulation is a feature [9,23]. This will
be discussed further, when the combined effects of
NRTIs and PIs are considered.
The contribution of PIs to lipodystrophy
As mentioned previously, the use of PI therapy is
strongly associated with the ‘metabolic syndrome’
component of the lipodystrophy syndrome. In keeping
with the observation that the introduction of PI
therapy is associated with changes in lipid and
glucose/insulin metabolism [5–8], cessation of PI
therapy and replacement by NRTI (abacavir) or
NNRTI therapy in ‘switching studies’ has been shown
to improve metabolic parameters [reviewed in 1]. In
relation to body composition changes, the interaction
of NRTIs and PIs is the dominant predictor of subcu-
taneous fat wasting as well as increased visceral
adiposity in PI-containing HAART [9]. Unfortunately,
the metabolic changes that accompany long-term dual
PI therapy are not well characterized at this time.
The ‘metabolic syndrome’ associated with PI
therapy (Figure 5) appears to be characterized by
increased levels of triglyceride and triglyceride-rich
lipoproteins (chylomicrons and VLDL-cholesterol).
These lipid fractions are normally elevated in the post-
prandial phase, and are destined for delipidation in the
peripheral circulation by the action of endothelial
lipoprotein lipase so that fatty acids may be removed
to adipose tissue and stored (after conversion to
triglyceride). Elevated plasma triglyceride levels are
accompanied by increased total, VLDL- and IDL-
cholesterol, apolipoproteins B and CIII as well as E,
and small-dense LDL-cholesterol as well as increased
HDL3 [23,63–67]. Although total LDL-cholesterol is
often not elevated, or elevations are mild, this pheno-
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A-FABP Mediate FA activation of PPAR-γ
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•TG synthesis from FFA: 4 ATP
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Figure 4. Role of mitochondria in adipose tissue
Triglyceride (TG) synthesis and storage (the major functions of adipose tissue)
are energy-requiring processes. Depletion of ATP activates the AMP-activated
protein kinase pathway, which inhibits triglyceride synthesis and de novo fatty
acid synthesis from carbohydrate precursors. AMPK activation also inhibits
lipolysis (fatty acid release from the adipocyte) by a direct effect on hormone-
sensitive lipase. Hence, mitochondrial dysfunction in adipocytes limits
lipogenesis and lipolysis, and directs metabolism towards oxidation while
increasing basal glucose uptake. Mt, mitochondrial; FA, fatty acid; FFA, free
fatty acid; CHO. cholesterol; HSL, hormone-sensitive lipase; AMPK, AMP-acti-
vated kinase; mtGPAT, mitochondrial glycerol phophate acyltransferase.type is now known to confer excess cardiovascular risk
– an issue addressed in a previous review [1]. A case
report demonstrating the ‘unmasking’ of ApoE2/E2-
related dysbetalipoproteinaemia by PI therapy
(ritonavir and indinavir) highlights a possible role for
defective clearance of apolipoprotein E-containing
lipids [68].
These lipid changes are commonly accompanied by
elevated insulin levels, and increased levels of free fatty
acid have also been observed [9,64]. Dysregulated fatty
acid metabolism was also found in a study by Sekhar
et al., [69] who used stable isotope tracer techniques to
provide a comprehensive assessment of in vivo lipid
metabolism dynamics in patients receiving PI-based
HAART. Turnover of fatty acids was found to be
dramatically increased, with elevated fat oxidation and
re-esterification in adipose and liver, increased 
lipolysis, and markedly decreased clearance of triglyc-
eride-enriched VLDL and chylomicrons (Figure 4).
This metabolic phenotype is typical of defective
post-prandial lipid metabolism, which in turn is inti-
mately associated with insulin resistance. A critical role
for insulin is the production of a coordinated metabolic
response to the post-prandial (or ‘fed’) state, so that
carbohydrates are used as the primary source of fuel
for oxidative reactions, while lipids are directed into
adipose stores for use when metabolism must rely more
heavily on fatty acids as a fuel source (in the post-
absorptive or ‘fasted’ state). Hence, increasing levels of
insulin following food intake increase fatty acid uptake
and triglyceride synthesis within adipocytes, and
inhibit lipolysis (free fatty acid release from triglyc-
eride) from adipose stores. A primary defect in insulin
signalling will, therefore, inevitably produce abnormal
post-prandial lipid metabolism. An alternative scenario
also exists, in which defective post-prandial lipid
metabolism may induce insulin resistance (as would be
predicted if lipoprotein-receptor-related protein (LRP)
[70], or the acylation-stimulating protein pathway [71]
were involved in pathogenesis).
The possibility that adipose tissue may be a target of
PI-mediated effects is supported by a number of in
vitro studies indicating that pharmacological doses of
PI drugs may directly induce insulin resistance in
adipocytes [72–74], as well as a defect in the late stages
of adipocyte maturation. This block in the adipocyte
differentiation programme occurs after the adoption of
adipocyte morphology, and is characterized by
decreased expression of nuclear transcription factors
C/EBP-α and PPAR-γ [72,75–77]. These studies have
also identified sterol regulatory element-binding
protein (SREBP) as a candidate factor that may
mediate these effects [72,76,78]. This endoplasmic
reticulum-derived transcription factor, common to
D Nolan et al.
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Figure 5. Insulin resistance and lipid metabolism
Insulin resistance decreases delipidation of chylomicrons (derived from dietary fat) and VLDL-cholesterol (from hepatic processing of fatty acids) at the level of
lipoprotein lipase, which is produced and secreted by adipocytes in response to insulin (Figure 6). Increased lipolysis from adipocytes, as well as increased chylomicron
remnants, increase hepatic processing to produce VLDL-cholesterol. VLDL metabolism normally produces LDL, which is then readily cleared by LDL receptors. ‘Altered’,
triglyceride-enriched VLDL, however, is diverted towards the production of IDL from HDL, as well as small, dense LDL that is less effectively cleared via the LDL
receptor and is more susceptible to oxidative modification.adipose tissue and the liver, appears to play a critical
role in inducing the signature adipocyte response to
post-prandial insulin release. In adipocytes it is
involved (either directly or via downstream stimulation
of PPAR-γ ) in increasing fatty acid uptake (lipoprotein
lipase) and fatty acid synthesis from carbohydrate
precursors (fatty acid synthase), inhibiting lipolysis
(hormone sensitive lipase), and increasing adipocyte
differentiation, as well as increasing uptake and utiliza-
tion of glucose as energy substrate (GLUT-4,
glucokinase) (Figure 6) [79–81]. Caron et al. [72] have
provided some clues to the site of a PI-induced defect
in SREBP activity, demonstrating that PI therapy inhib-
ited the translocation of active SREBP-1c from
endoplasmic reticulum and nuclear membranes to the
nucleus. They also detected altered electrophoretic
mobility of activated SREBP-1, suggesting abnormal
processing or phosphorylation of active SREBP after
proteolytic activation from its 125 kDa precursor
form. Interestingly, defective SREBP processing may
also be central to the pathogenesis of Dunnigan-type
familial partial lipodystrophy, a severe monogenic
form of insulin resistant lipodystrophy that resembles
HAART-associated lipodystrophy phenotypically [82].
The underlying genetic defect in this condition involves
mutations in the LMNA gene that encodes nuclear
lamin A, a protein involved in the organisation of the
nuclear membrane and the regulation of trafficking of
transcription factors into the nucleus. It has been
proposed that mutated LMNA products may interact
abnormally with SREBP, so that activation of nuclear
transcription factors is impaired [82] (Figure 6).
Could adipose-selective insulin resistance be central
to the PI-associated ‘metabolic syndrome’, and to the
interaction between NRTIs and PIs in the development
of subcutaneous fat wasting? Certainly, interest in the
possibility that adipose tissue, rather than muscle, may
be the central regulator in insulin resistance has been
revived by a number of recent observations [83]. Mice
with an adipose-specific reduction of GLUT4 (the
insulin-responsive glucose transporter) also developed
insulin resistance in muscle and liver [84], and the
subsequent isolation of resistin, an adipose-derived
protein, has provided a plausible mechanism whereby
defective adipose insulin signalling determines more
generalized insulin resistance [85].
A recognition of depot-specific differences between
subcutaneous and visceral fat is important when
considering these effects, particularly in the context of
HIV lipodystrophy in which subcutaneous fat wasting
may be accompanied by visceral fat accumulation.
Subcutaneous fat acts as a more efficient and stable fat
storage reservoir, with greater triglyceride synthetic
capacity [71] and responsiveness to insulin [86], indi-
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Figure 6. Sterol regulatory element-binding protein and peroxisome proliferator activated receptor γ insulin signalling pathways
in adipocytes
Sterol regulatory element-binding protein is activated by insulin, and acts to promote lipogenesis and adipocyte differentiation via multiple pathways, acting both
directly and via intranuclear activation of peroxisome proliferator activated receptor γ / retinoid-X receptor nuclear transcription factors. SREBP, sterol regulatory
element-binding protein; IRS-2, insulin receptor substrate-2; PI3-kinase, phosphotidylinositol 3-kinase; PKB, protein kinase B; PPAR-γ , peroxisome proliferator acti-
vated receptor γ ; RXR, retinoid-X receptor.cating a bias towards lipogenesis. This is also
supported by the fact that subcutaneous preadipocytes
differentiate more readily to mature adipocytes in
response to PPAR-γ agonists [87]. Visceral adipose
tissue, on the other hand, is a more labile fat store with
increased lipid turnover and greater expression of
specific receptors for hormones that promote lipid
accumulation (cortisol) as well as lipolysis (androgens,
growth hormone, catecholamines) [88]. Lipoprotein
lipase (LPL) activity is also higher in visceral adipose
tissue in males and females [89]. Significantly,
increased fatty acid levels promote insulin resistance in
subcutaneous fat and muscle, while visceral adipose
tissue responds by increasing glucose use and GLUT4
expression (as well as PPAR-γ and CD36/fatty acid
translocase), thus channelling fatty acids towards the
visceral fat depot, presumably in an attempt to limit
lipotoxic damage to other organs [90]. Visceral fat
accumulation, then, may represent an adaptive
response to insulin resistance and dysregulated fatty
acid metabolism [91], even in the context of adipose-
specific insulin resistance. Given the role of visceral fat
as a hormonally-responsive adipose depot, the
hormonal changes that have been seen to evolve with
the development of lipodystrophy (for example,
increasing cortisol/DHEA ratios [63], changes in
growth hormone dynamics [92], and hyperandroge-
naemia in women [93]) may be primarily determined
by visceral adiposity per se, rather than its underlying
cause.
Adipocyte insulin resistance and impaired matura-
tion has been demonstrated in vitro in the presence of
indinavir, nelfinavir, ritonavir, saquinavir and ampre-
navir in the studies previously mentioned [72–77],
suggesting that this is a class effect of PIs. As previously
mentioned, ritonavir use appears to be associated with
relatively greater increases in triglyceride levels
compared with other PI drugs [10,11]. Ritonavir
therapy in HIV-negative volunteers also induced
marked elevations of triglyceride-enriched lipoproteins
over a 2-week period (increased plasma triglyceride,
VLDL cholesterol, IDL cholesterol and apolipoprotein
B compared with controls and to baseline levels,
P<0.01 for all values) [5]. Unlike other HIV-1 protease
inhibitors, ritonavir appears to have activity as a
proteasome inhibitor [94], and shows specificity for a
proteasomal pathway involved in the degradation of
SREBP-1 [95]. Accordingly, ritonavir appears to act
mainly to increase hepatic triglyceride synthesis via
increased stabilization of nuclear SREBP-1c [96],
suggesting that its hypertriglyceridaemic activity may
be due to the additive effect of hepatic and adipose
targeting of ritonavir action. Similarly, it is possible
that the rapid induction of insulin resistance in HIV-
negative volunteers after 4 weeks’ exposure to
standard-dose indinavir therapy [6] may relate to the
ability of this drug to impair insulin signalling in
multiple insulin-responsive tissues, including liver [97]
and skeletal muscle [98] as well as adipose tissue. The
effects of other PI drugs are yet to be studied in these
tissues.
These  in vitro studies have provided some critical
insights into possible mechanisms underlying PI-
induced adverse effects. It is hoped that in vivo studies
that are informed by these results will be undertaken, in
which involved tissue (for example, adipose tissue) is
sampled and assessed. In this way, the clinical relevance
of these findings (and the relative effects of select PIs
within this class of drugs) may be determined.
Interactions of NRTIs and PIs – an
‘adipocentric’ model of lipodystrophy
Taken together, the proposed effects of NRTI-induced
mitochondrial dysfunction and PI-induced insulin
resistance/impaired maturation on adipocytes each
contribute to a disorganized lipid metabolism that
appears consistent with in vivo dynamic metabolism
studies [66] (Figure 7). Loss of the lipogenic and
triglyceride-storing capacity of adipose tissue is
central to this effect, so that lipid metabolism is unable
to respond appropriately to the ‘fed’ state.
Uncontrolled fatty acid flux represents a response to
loss of insulin signalling, producing an ongoing
‘fasting’ metabolic response in which fatty acid is
liberated from adipose tissue, and fat oxidation is
stimulated. While a diversion from triglyceride and
fatty acid biosynthesis to oxidative pathways within
the adipocyte appears to be common to the proposed
NRTI and PI effects, it could be predicted that NRTI-
induced mitochondrial dysfunction would lead to
decreased lipolysis, while loss of insulin sensitivity
would increase it. It is possible that the balance
between these two effects may determine if the pheno-
type is predominantly ‘lipoatrophic’, where NRTI
effects are prominent (with less evidence of insulin
resistance clinically, although triglyceride levels may
be higher [9,23]), or ‘mixed’, in which the presence of
visceral fat accumulation and insulin resistance indi-
cate that lipolysis is dysregulated and fatty acid flux is
increased (‘PI effect’) [9,23].
Does this model provide an explanation for the fact
that combining NRTI and PI therapy greatly increases
the risk of developing subcutaneous fat wasting
compared with the use of either drug class alone? One
clue may be provided by the adipose tissue
morphology that is seen in HAART-associated lipody-
strophy (Figure 3), in which increased mitochondrial
mass is accompanied by evidence of decreased cellular
volume (redundant basal lamina) and loss of the
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toplasmic deposits [47,48]. This phenotype is also
observed in ‘converted adipocytes’, described by
Himms-Hagen  et al. [99], in which diversion of
adipocyte metabolism towards fatty acid oxidation
(accomplished by β 3-adrenoceptor agonists in this
experimental setting) produces morphological changes
in mature adipocytes consistent with those seen in
lipodystrophy. These adipocytes are also characterized
by increased expression of uncoupling protein-3
(UCP-3), a mitochondrial protein induced by
increased cellular fatty acid levels [100]. These data
suggest that increasing adipocyte oxidative metabo-
lism, as is proposed for both NRTI and PI effects may:
(1) increase adipocyte mitochondrial mass indepen-
dent of the effects of mtDNA depletion or toxicity; (2)
increase intracellular fatty acid levels; and thus (3)
invoke mechanisms designed to limit cytotoxicity
associated with excessive fatty acid concentrations.
These responses may each contribute to enhancing
tissue mitochondrial dysfunction and cellular toxicity.
In particular, there is a well characterized mechanism
whereby increased cellular fatty acid levels induce
partial ‘uncoupling’ of mitochondrial respiration,
involving UCP-3 as well as other members of a closely
related family of mitochondrial inner membrane anion
transporters [101]. ‘Uncoupling’ refers to an imperfect
correlation between substrate use (glucose and fatty
acids) and subsequent ATP production within mito-
chondria, so that excessive substrates can be ‘burned’
to produce heat rather than ATP. This regulated
response minimizes the effects of excess fatty acids
(for example, increased reactive oxidative stress and
direct toxicity within mitochondria) while also
avoiding excessive ATP production (which would
inhibit multiple biochemical pathways within mito-
chondria) [101].
It may be proposed that the appropriate physiolog-
ical responses that are evoked by impaired
mitochondrial function induced by NRTIs (mediated
by AMP-activated kinase), and by insulin resistance
and increased fatty acid flux (mediated by fatty acid
induced uncoupled respiration) are incompatible, and
lead to a pathophysiological state in which the cell is
unable to achieve energy homoeostasis. In this
scenario, a ‘vicious metabolic cycle’ is created, in
which restoration of the ADP/ATP ratio in response to
mitochondrial dysfunction (‘energy depletion’) is
subverted by an ongoing demand for decreased effi-
ciency of mitochondrial respiration by increased fatty
acids (‘fuel excess’).
A possible clinical correlate for this hypothesis has
been provided by Kosmiski et al. [102], who demon-
strated increased resting energy expenditure (REE) in
patients receiving PI-based HAART, consistent with data
in other insulin resistant lipodystrophy syndromes.
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Intracellular triglyceride stores in adipocytes are determined by the dynamic equilibrium between triglyceride synthesis (in turn dependent on fatty acid uptake or
re-esterification, and/or fatty acid synthesis from carbohydrate precursors, as well as assembly of fatty acids and glycerol to form triglyceride); and triglyceride lipol-
ysis (by hormone sensitive lipase) and export of liberated fatty acids from the cell. In the presence of mitochondrial dysfunction (‘NRTI effect’), both processes are
inhibited while energy is conserved so that the adipocyte can meet its own bioenergetic requirements. This ‘isolates’ the cell from the demands of whole-body
metabolism, and causes a shift from energy storage (as triglyceride) to energy use, including fat oxidation. Adipose insulin resistance (‘PI effect’) would be predicted
to cause loss of the post-prandial insulin response in adipocytes, resulting in reduced triglyceride storage and increased fatty acid oxidation, decreased adipocyte
differentiation, and inappropriate activation of lipolysis in the post-prandial phase.Elevated metabolic rate in HAART recipients had been
noted in a previous report, in which no association
between immunological or virological parameters and
REE was found [103]. However, Kosmiski et al. have
demonstrated that metabolic, rather than antiviral,
effects of PI therapy appear to determine increased REE,
which was found to be ~25% higher than predicted in
patients receiving PI-based HAART with clinical
evidence of lipodystrophy and ~6% higher in those
without clinically apparent lipodystrophy [102]. This
effect was not abrogated by adjustment for the expected
influence of fat free mass. A strong negative correlation
between accurately measured insulin sensitivity and REE
was found (correlation coefficient =–0.68, P<0.005),
and subsequent logistic regression analysis suggested
that insulin resistance was the major determinant of
REE independent of any effects of therapy on body
composition (measured by DEXA scanning and lumbar
computed tomography scans).
These findings may provide in vivo evidence of fatty
acid-induced uncoupling, as increased metabolism in the
resting state is likely to represent the consequences of
uncoupled mitochondrial respiration, while accurately
measured insulin resistance would be predicted to
provide a marker of increased tissue fatty acid flux.
The role of inner mitochondrial membrane trans-
porters such as the UCPs is also interesting from the
point of view of NRTI effects. As stated previously, the
characterization of a mitochondrial deoxynucleotide
carrier with a high affinity for activated (triphosphory-
lated) NRTIs represents a major advance in this area of
research [33]. This transmembrane protein has signifi-
cant homology with other members of the
mitochondrial membrane transporter family (including
uncoupling proteins as well as transporters critical to
mitochondrial respiratory chain function such as the
ADP/ATP translocator), so it is conceivable that interac-
tions with other transporters by NRTIs could influence
fatty acid handling and mitochondrial function through
direct non-‘pol-γ ’ mechanisms. In this context, there is a
body of evidence that zidovudine interacts with the
muscle isoform of the ADP/ATP translocator, a factor
that may have had a role in the pathogenesis of
myopathy associated with this drug [104–106]. It is
possible that direct dose-dependent NRTI effects on a
transporter preferentially distributed in adipose tissue
(for example, dicarboxylate carrier [107]) could explain
why these hydrophilic drugs affect adipocytes preferen-
tially.
Host factors
While this review has focused on the contributions of
NRTI and PI therapy to the lipodystrophy syndrome,
we do not wish to discount the important contribution
of host factors in determining susceptibility, severity
and phenotypic expression of the lipodystrophy
syndrome. For example, gender and racial origin
appear to influence the lipodystrophy phenotype, with
an increased risk of subcutaneous fat wasting among
white males, while women and non-white males
appear to be more prone to develop visceral fat accu-
mulation. This finding has been reviewed recently
[108]. It is pertinent to mention, however, that much of
the clinical data that have been presented in both this
and a previous review [1] have been obtained from
white male patient populations, and may therefore not
apply universally.
The role of host factors is also demonstrated in
studies in which polymorphisms in genes for the β 3-
adrenergic receptor [109] (involved in regulating
lipolysis in visceral fat) and for tumour necrosis factor-
α cytokine [110] (which is secreted by adipocytes and
has been implicated in the pathogenesis of insulin resis-
tance [111]) have been associated with altered
lipodystrophy outcomes. In the future, it is likely that
further host factors will emerge that significantly influ-
ence susceptibility to lipodystrophy (for example, by
preventing drug-specific toxic effects such as mito-
chondrial toxicity) as well as the severity of metabolic
and/or morphologic consequences of the syndrome.
Conclusions
There is still much to learn of the mechanisms that are
involved in the development of both morphologic and
metabolic components of the lipodystrophy syndrome
in individuals receiving HAART, and we look forward
to the further elucidation of these factors at the cellular
and subcellular level. While the proposed ‘adipocen-
tric’ model is necessarily simplistic in its approach to
the interaction between NRTIs and PIs, at this point it
is sufficient to broadly explain the clinical phenotype.
There is no doubt that compensatory as well as
contributory effects in other tissues will play a role,
and that host factors also influence susceptibility to,
and phenotypic expression of, the syndrome.
Characterizing these factors will certainly provide for a
more comprehensive aetiopathogenic model.
In conclusion, NRTIs and PIs have specific affects
on metabolism that are removed from their antiviral
activity, and are synergistic in adipose tissue. The inter-
action of NRTIs and PIs induces a phenotype in which
fat storage is diminished while fat use is enhanced,
associated with loss of the usual metabolic responses to
the ‘fed’ state. In this setting, reduction in subcuta-
neous adipose tissue mass is likely to be a consequence
of adipose atrophy as well as adipocyte loss, while
accumulation of fat in the visceral compartment repre-
sents a response to increased fatty acid flux and insulin
D Nolan et al.
©2001 International Medical Press 156resistance. Further elucidation of the mechanisms
involved will aid the development of appropriate ther-
apeutic and management strategies, as well as guide the
safer use of combination antiretroviral therapies.
References
1. John M, Nolan D & Mallal S. Antiretroviral therapy and
the lipodystrophy syndrome. Antiviral Therapy 2001;
6:9–20.
2. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F,
Rouviere O, Lang JM, Gastaut JA & Touraine JL. A
syndrome of peripheral fat wasting (lipodystrophy) in
patients receiving long-term nucleoside analogue therapy.
AIDS 1999; 13:1659–1667.
3. Polo R, Verdejo J, Martinez-Rodriguez S, Madrigal P &
Gonzalez-Munoz M. Lipopatrophy, fat accumulation, and
mixed syndrome in protease inhibitor-naive HIV-infected
patients. Journal of Acquired Immune Deficiency
Syndromes 2000; 25:284–285.
4. Mallal SA, John M, Moore CB, James IR & McKinnon EJ.
Contribution of nucleoside analogue reverse transcriptase
inhibitors to subcutaneous fat wasting in patients with HIV
infection. AIDS 2000; 14:1309–1316.
5. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R &
Leonard JM. Effect of ritonavir on lipids and post-heparin
lipase in normal subjects. AIDS 2000; 14:51–57.
6. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA,
Schambelan M, et al. Metabolic effects of indinavir in
healthy HIV-seronegative men. AIDS 2001; 15:11–18.
7. Mulligan K, Grunfeld, Tai VW, Algren H, Pang M,
Chernoff DN, Lo JC & Schambelan M. Hyperlipidemia
and insulin resistance are induced by protease inhibitors
independent of change in body composition in patients with
HIV infection. Journal of Acquired Immune Deficiency
Syndromes 2000; 23:35–43.
8. Wanke C, Gerrior J, Skinner S, McNamara JR & Schaefer
EJ. Lipid profiles in HIV-infected patients before and after
protease inhibitor therapy. 2
nd International Workshop on
Adverse Drug Reactions and Lipodystrophy in HIV.
Toronto Canada, 13–15 September 2000, Abstract P8.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distri-
bution evaluated by computed tomography and metabolic
abnormalities in patients undergoing antiretroviral therapy:
preliminary results of the LIPOCO study. AIDS 2000;
14:37–49.
10. Tsiodras S, Mantzoros C, Hammer S & Samore M. Effects
of protease inhibitors on hyperglyceamia, hyperlipidaemia,
and lipodystrophy. A 5-year cohort study. Archives of
Internal Medicine 2000;160:2050–2056.
11. Thiebaut R, Dabis F, Malvy D, Jaqmin-Gadda H, Mercie P
& Daucourt V. Serum triglycerides, HIV infection, and
highly active antiretroviral therapy, Aquitaine cohort,
France, 1996 to 1998. Journal of Acquired Immune
Deficiency Syndromes 2000; 23:261–265.
12. Law M, Emery S, French M, Carr A, Chuah J & Cooper D.
Lipodystrophy and metabolic abnormalities in a cross-
sectional study of participants in randomised controlled
studies of combination antiretroviral therapy. 2nd
International Workshop on Adverse Drug Reactions and
Lipodystrophy in HIV. Toronto, Canada, 13–15 September
2000, Abstract 028.
13. Joly V, Flandre P, Meiffredy V, Hazebrouck S, Harel M,
Aboulker JP & Yeni P. Assessment of lipodystrophy in
patients previously exposed to AZT, ddI or ddC, but naïve
for d4T and protease inhibitors (PI), and randomised
between d4T/3TC/Indinavir and AZT/3TC/Indinavir
(NOVAVIR trial). 8th Conference on Retroviruses and
Opportunistic Infections. Chicago, Ill, USA, 4–8 February
2001, Abstract 539.
14. Molina JM, Angelini E, Cotte L, et al. Prevalence of
lipodystrophy in long term follow up of a clinical trial
comparing various combinations of nucleoside analogue
reverse transcriptase inhibitors (NRTI), ALBI trial:ANRS
070. 7th Conference on Retroviruses and Opportunistic
Infections. San Francisco, Calif., USA, 30 January
–February 2 2000, Abstract 19
15. Van der Walk M, Gisolf EH, Reiss P, Wit FWNM, Japour
A, Weverling GJ, et al. Increased risk of lipodystrophy when
nucleoside analogue reverse transcriptase inhibitors are
included with protease inhibitors in the treatment of HIV-1
infection. AIDS 2001; 15:847–855.
16. Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der
Ende ME, Brinkman K, et al. (Prometheus Study Group).
The effect of treatment intensification in HIV-infection: a
study comparing treatment with ritonavir/saquinavir and
ritonavir/saquinavir/stavudine. AIDS 2000; 14:405–413.
17. Cohen C, Cameron W, Xu Y, Rode R, Mellors J, Farthing
C, Poretz D, Markovitz, D, Ho D, McMahon D, Drennon
D, Selness K, Ryan J, Sun E & Japour AJ. Effect of NRTI
intensification on prevalence of body composition abnor-
malities at week 144 of ritonavir plus saquinavir therapy in
an HIV-infected cohort. 2nd International Workshop on
Adverse Drug Reactions and Lipodystrophy in HIV.
Toronto, Canada, 13–15 September 2000, Abstract P56.
18. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing
C, et al. Ritonavir and saquinavir combination therapy for
the treatment of HIV infection. AIDS 1998; 13:213–224.
19. Polo R, Verdejo J, Martinez-Rodriguez S, Madrigal P &
Gonzalez-Munoz M. Lipodystrophy in protease-inhibitor-
naive HIV-infected patients. 40th Interscience Conference
on Antimicrobial Agents and Chemotherapy, Toronto,
Canada, 17–20 September 2000, Abstract 1282.
20. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I
& Falloon J. Visceral abdominal-fat accumulation associ-
ated with use of indinavir. Lancet 1998; 351:871–875.
21. Galli M, Ridolfo AL, Gervasoni C, Santambrogio S,
Ravasio L, Corsico L, et al. Risk of developing metabolic
alterations in PI-naive HIV-1 infected patients treated with
RTI. 40th Interscience Conference on Antimicrobial Agents
and Chemotherapy. Toronto, Canada, 17–20 September
2000, Abstract 1292.
22. Wit FWNM, Gisolf EH, Oostwegel LMM, Weverling GJ,
Lange JMA, Reiss P, et al. Stavudine use is not associated
with an incremental risk of hyperlipidaemia during treat-
ment with HIV-1 protease inhibitors. 1st International
Workshop on Adverse Drug Reactions and Lipodystrophy
in HIV. San Diego, Calif. USA, 26–28 June 1999, Abstract
O65.
23. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S,
Basgoz N, et al. Metabolic abnormalities and cardiovas-
cular disease risk factors in adults with human
immunodeficiency virus infection and lipodystrophy.
Clinical Infectious Diseases 2001; 32:130–139.
24. Ware LJ, Morlese J, Burdge G, Jackson AA, Gazzard B &
Wootton SA. Differences in postprandial lipid metabolism
in patients with PI-associated and NRTI-associated lipodys-
trophy. 2nd International Workshop on Adverse Drug
Reactions and Lipodystrophy in HIV. Toronto, Canada,
13–15 September 2000, Abstract O20.
25. Paulik M, Lancaster M, Croom D, Spencer D, Weiel J,
Lenhard J. Anti-oxidants rescue NRTI-induced metabolic
changes in AKR/J mice. 2nd International Workshop on
Adverse Drug Reactions and Lipodystrophy in HIV.
Toronto, Canada, 13–15 September 2000, Abstract O8.
26. Isola LM, Zhou S-L, Kiang C-L, Stump DD, Bradbury MW
& Berk PD. 3T3 fibroblasts transfected with a cDNA for
mitochondrial aspartate aminotransferase express plasma
membrane fatty acid-binding protein and saturable fatty
acid uptake. Proceedings of the National Academy of
Sciences, USA 1995; 92:9866–9870.
27. Bradbury MW & Berk PD. Mitochondrial aspartate amino-
transferase: direction of a single protein with to distinct
functions to two subcellular sites does not require alterna-
tive splicing of the mRNA. The Biochemical Journal 2000;
348:423–427.
28. Longley MJ, Ropp PA, Lim SE & Copeland WC.
Characterization of the native and recombinant catalytic
Antiviral Therapy 6:3 157
Antiviralretoviral therapy and the lipodystrophy syndromesubunit of human DNA polymerase γ : Identification of
residues critical for exonuclease activity and dideoxynu-
cleotide sensitivity. Biochemistry 1998; 37:10529–10539.
29. Brinkman K, Smetink JA, Romjin JA & Reiss P.
Mitochondrial toxicity induced by nucleoside analogue
reverse-transcriptase inhibitors is a key factor in the patho-
genesis of antiretroviral-therapy-related lipodystrophy.
Lancet 1999; 354: 1112–1115.
30. Kakuda TN. Pharmacology of nucleoside and nucleotide
reverse transcriptase inhibitor-induced mitochondrial toxi-
city. Clinical Therapeutics 2000; 22:685–708.
31. White AJ. Mitochondrial toxicity and HIV therapy.
Sexually Transmitted Infections 2001; 77:158–173.
32. Martin JL, Brown CE, Matthews-Davis N & Reardon JE.
Effects of antiviral nucleoside analogs on human DNA
polymerases and mitochondrial DNA synthesis.
Antimicrobial Agents & Chemotherapy 1994;
38:2743–2749.
33. Dolce V, Fiermonte G, Runswick MJ, Palmieri F & Walker
JE. The human mitochondrial deoxynucleotide carrier and
its role in the toxicity of nucleoside antivirals. Proceedings
of the National Academy of Sciences, USA 2001;
98:2284–2288.
34. Dudley MN. Clinical pharmacokinetics of nucleoside anti-
retroviral agents. Journal of Infectious Diseases 1995;
171(Suppl. 2):S99–S112.
35. Somadossi J-P. Comparison of metabolism and in vitro
antiviral activity of stavudine versus other 2′ -3′ -dideoxynu-
cleoside analogues. Journal of Infectious Diseases 1995;
171(Suppl. 2):S88–S92.
36. Wang L, Munch-Petersen B, Sjoberg AH, Hellman U,
Bergman T, Jornvall H & Eriksson S. Human thymidine
kinase 2: molecular cloning and characterisation of the
enzyme activity with antiviral and cytostatic nucleoside
substrates. FEBS Letters 1999; 443:170–174.
37. Rampazzo C, Gallinaro L, Milanesi E, Frigimelica E,
Reichard P & Bianchi V. A deoxyribonucleotidase in mito-
chondria: Involvement in regulation of dNTP pools and
possible link to genetic disease. Proceedings of the
National Academy of Sciences, USA 2000; 97:8239–8244.
38. Lavie A, Ostermann N, Brundiers R, Goody RS, Reinstein
J, Konrad M & Schlichting I. Structural basis for efficient
phosphorylation of 3′ -azidothymidine monophosphate by
Escherichia coli thymidylate kinase. Proceedings of the
National Academy of Sciences, USA 1998;
95:14045–14050.
39. Arner ESJ, Spasokoukotskaja T & Erikkson S. Selective
assays for thymidine kinase 1 and 2 and deoxycytidine
kinase and their activities in extracts from human cells and
tissues. Biochemical and Biophysical Research
Communications 1992; 188:712–718.
40. Wang J, Su C, Neuhard J & Eriksson S. Expression of
human mitochondrial thymidine kinase in Escherichia coli:
correlation between the enzymatic activity of pyrimidine
nucleoside analogues and their inhibitory effect on bacte-
rial growth. Biochemical Pharmacology 2000;
59:1583–1588.
41. Turriziani O. Simeoni E, Dianzani F & Antonelli G. Anti-
HIV antiviral activity of stavudine in a thymidine
kinase-deficient cellular line. Antiviral Therapy 1998;
3:191–194.
42. Cui L, Locatelli L, Xie M-Y & Sommadossi J-P. Effect of
nucleoside analogs on neurite regeneration and mitochon-
drial DNA synthesis in PC-12 cells. The Journal of
Pharmacology and Experimental Therapeutics 1997;
280:1228–1234.
43. Johansson M, Karlsson A. Cloning and expression of
human deoxyguanosine kinase cDNA. Proceedings of the
National Academy of Sciences, USA 1996; 93:7258–7262.
44. Walker UA, Bickel M, Lutke Volksbeck SI, Schofer H,
Setzer B, Rickerts V, et al. Decrease of mitochondrial DNA
content in adipose tissue of HIV-1-infected patients treated
with NRTIs. Antiviral Therapy 2000; 5 (Suppl. 5):5.
45. Shikuma C, Hu N, Milne C, Yost F, Shimizu S, Shiramizu
B. Analysis of subcutaneous adipose tissue mitochondrial
DNA from individuals with HAART-associated lipodys-
trophy. 8th Conference on Retroviruses and Opportunistic
Infections. Chicago, Ill., USA, 4–8 February 2001, Abstract
665.
46. Mallal SA, Hammond EL, Martin A, Taylor L, John M &
Nolan DA. Mitochondrial DNA depletion, assessed by
real-time PCR-based quantitative assay, in subcutaneous fat
of HIV-infected patients: evidence for a role in the etiology
of fat wasting. 4th International Conference on Nutrition
and HIV Infection. Cannes, France, 19–21 April 2001,
Abstract O7.
47. Mallal S, Nolan D, John M, Chong D, Metcalf C &
Latham B. Light and electron microscopy findings in
subcutaneous fat in antiretroviral treated and HIV-infected
patients. XIII International AIDS Conference. Durban,
South Africa 2000, Abstract LpPeB7054.
48. Lloreta J, Domingo P, Pujol R, Arroyo J, Sambeat M &
Serrano S. An ultrastructural insight into the pathogenesis
study of HAART-associated partial lipodystrophy. 1st IAS
Conference on HIV Pathogenesis and Treatment. Buenos
Aires, Argentina, 8–11 July 2001, Abstract 494.
49. Chow CW & Thorburn DR. Morphologic correlates of
mitochondrial dysfunction in children. Human
Reproduction 2000; 15 (Suppl 2):68–78.
50. Linnane AW, Degli Esposti M, Generowicz M, Luff AR &
Nagley P. The universality of bioenergetic disease and
amelioration with redox therapy. Biochimica et Biophysica
Acta 1995; 127:191–194.
51. Frayn KN. Metabolism regulation. A human perspective.
1996; pp 72–80. London, UK : Portland Press.
52. Kang J, Heart E & Sung CK. Effects of cellular ATP deple-
tion on glucose transport and insulin signalling in 3T3-L1
adipocytes. American Journal of Physiology Endocrinology
and Metabolism 2001; 280:E428–E435.
53. Rossmeisl M, Syrovy I, Baumurk F, Flachs P, Janovska P &
Kopecky J. Decreased fatty acid synthesis due to mitochon-
drial uncoupling in adipose tissue. FASEB Journal 2000;
14:1793–1800.
54. Winder W, Hardie DG. AMP-activated protein kinase, a
metabolic master switch: possible roles in Type 2 diabetes.
American Journal of Physiology 1999; 277:E1–E10.
55. Ruderman NB, Saha AK, Vavvas D & Witters LA.
Malonyl-CoA, fuel sensing, and insulin resistance.
American Journal of Physiology 1999; 276:E1–E18.
56. Hardie DG, Carling D & Carlson M. The AMP-
activated/SNF1 protein kinase subfamily: metabolic sensors
of the eukaryotic cell? Annual Review of Biochemistry
1998; 67:821–855.
57. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling
D & Beri RK. Inhibition of lipolysis and lipogenesis in
isolated rat adipocytes with AICAR, a cell-permeable acti-
vator of AMP-activated protein kinase. FEBS Letters 1994;
353:33–36.
58. Soltys BJ & Gupta RS. Mitochondrial proteins at unex-
pected locations: export of proteins from mitochondria
from an evolutionary perspective. International Review of
Cytology 1999; 194:133–196.
59. Zhou S-L, Stump D, Kiang C-L, Isola LM & Berk PD.
Mitochondrial aspartate aminotransferase expressed on the
surface of 3T3-L1 adipocytes mediates saturable fatty acid
uptake. Proceeding of the Society for Experimental Biology
and Medicine 1995; 208:263–270.
60. Hertzel AV & Bernlohr DA. Regulation of adipocyte gene
expression by polyunsaturated fatty acids. Molecular and
Cellular Biochemistry 1998; 188:33–39.
61. Shen W-J, Sridhar K, Bernlohr DA & Kraemer FB.
Interaction of rat hormone-sensitive lipase with adipocyte
lipid-binding protein. Proceedings of the National
Academy of Sciences, USA 1999; 96:5528–5532.
62. Coe NR, Simpson MA & Bernlohr DA. Targeted disrup-
tion of the adipocyte lipid-binding protein (aP2 protein)
gene impairs fat cell lipolysis and increases cellular fatty
acid levels. Journal of Lipid Research 1999; 40:967–972.
D Nolan et al.
©2001 International Medical Press 15863. Christeff N, Melchior J-C, de Truchis P, Perronne C,
Nunez EA & Gougeon M-L. Lipodystrophy defined by a
clinical score in HIV-infected men on highly active anti-
retroviral therapy: correlation between dyslipidaemia and
steroid hormone alterations. AIDS 1999; 13:2251–2260.
64. Vigouroux C, Gharakanian S, Salhi Y, Nguyen T-H,
Chevenne D, Capeau J, et al. Diabetes, insulin resistance
and dyslipidaemia in lipodystrophic HIV-infected patients
on highly active antiretroviral therapy (HAART). Diabetes
Metabolism 1999; 25:225–232.
65. Bonnet E, Ruidavets J-B, Tuech J, Ferrieres J, Collet X,
Fauvel J, et al. Apoprotein C-III and E-containing lipopar-
ticles are markedly increased in HIV-infected patients
treated with protease inhibitors: association with the devel-
opment of lipodystrophy. Journal of Clinical
Endocrinology and Metabolism 2001; 86:296–302.
66. Behrens G, Dejam A, Schmidt H, Balks H-J, Brabant G,
Korner T, et al. Impaired glucose tolerance, beta cell func-
tion and lipid metabolism in HIV patients under treatment
with protease inhibitors. AIDS 1999;13:F63–F70.
67. Berthold HK, Parhofer KG, Ritter MM, Addo M,
Wasmuth JC, Schliefer K, et al. Influence of protease
inhibitor therapy on lipoprotein metabolism. Journal of
Internal Medicine 1999; 246:567–575.
68. Lister RK, Youle M, Nair DR, Winder AF & Rustin MHA.
Latent dysbetalipoproteinaemia precipitated by HIV-
protease inhibitors. Lancet 1999; 353:1678.
69. Sekhar RV, White AC Jr, Jahoor F, Visnegarwala F, Reeds
PJ & Balasubramanyam B. HIV-associated fat redistribu-
tion is associated with marked acceleration of lipid
turnover. 8th Conference on Retroviruses and
Opportunistic Infections. Chicago, Ill., USA, 4–8 February
2001, Abstract 663.
70. Carr A, Samaras K, Chisholm DJ & Cooper DA.
Pathogenesis of HIV-1 protease inhibitor-associated periph-
eral lipodystrophy, hyperlipidaemia, and insulin resistance.
Lancet 1998; 352:1881–1883.
71. Sniderman AD, Cianflone K, Arner P, Summers LKM &
Frayn KN. The adipocyte, fatty acid trapping, and athero-
genesis. Arteriosclerosis, Thrombosis and Vascular Biology
1998;18:147–151.
72. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C
& Capeau J. The HIV-protease inhibitor indinavir impairs
sterol regulatory element-binding protein-1 intranuclear
localization, inhibits preadipocyte differentiation, and
induces insulin resistance. Diabetes 2001; 50:1378–1388.
73. Rudich A, Vanounou S, Reisenberg K, Porat M, Tirosh A,
Harman-Bochm H, et al. The HIV protease inhibitor nelfi-
navir induces insulin resistance and increases basal lipolysis
in 3T3-L1 adipocytes. Diabetes 2001; 50:1425–1431.
74. Murata H, Hruz PW & Mueckler M. The mechanism of
insulin resistance caused by HIV protease inhibitor therapy.
Journal of Biological Chemistry 2000; 275:20251–20254.
75. Stevens GJ, Lankford AC, Chen M & Jessen B. Inhibition
of adipocyte differentiation in HIV-1 protease inhibitors:
potential mechanisms based on changes in gene expression.
Antiviral Therapy 2000; 5 (Suppl. 5):26.
76. Dowell P, Flexner C, Kwiterich PO & Lane MD.
Suppression of preadipocyte differentiation and promotion
of adipocyte death by HIV protease inhibitors. Journal of
Biological Chemistry 2000; 275:41325–41332.
77. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J,
Moller DE. Inhibition of adipocyte differentiation by HIV
protease inhibitors. Journal of Clinical Endocrinology &
Metabolism 1999; 84:4274–4277.
78. Miserez AR, Barella L, Muller PY, Schwietert M, Erb P,
Klimkait T, et al. Hyperlipoproteinaemia in HIV patients is
linked to sterol-regulatory element-binding protein
(SREBP)-1c. 8th Conference on Retroviruses and
Opportunistic Infections. Chicago, Ill., USA, 4–8 February
2001, Abstract 500.
79. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin
G, et al. Regulation of peroxisome proliferator-activated
receptor γ expression by Adipocyte Differentiation and
Determination Factor 1/Sterol Regulatory Element Binding
Protein 1: implications for adipocyte differentiation and
metabolism. Molecular and Cellular Biology 1999;
19:5495–5503.
80. Flier JS & Hollenberg AN. ADD-1 provides new insight
into the mechanisms of insulin action. Proceedings of the
National Academy of Sciences, USA 1999;
96:14191–14192.
81. Osborne TF. Sterol Regulatory Element-binding Proteins
(SREBPs): key regulators of nutritional homeostasis and
insulin action. Journal of Biological Chemistry 2000;
275:32379–32382.
82. Hegele RA. Molecular basis of partial lipodystrophy and
prospects for therapy. Trends in Molecular Medicine 2001;
7:121–126.
83. Birnbaum MJ. Dialogue between muscle and fat. Nature
2001; 409:672–673.
84. Abel ED, Peroni O, Kim JK, Kim Y-B, Boss O, Hadro E, et
al. Adipose-selective targeting of the GLUT4 gene impairs
insulin action in muscle and liver. Nature 2001;
409:729–733.
85. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR,
Wright CM, et al. The hormone resistin links obesity to
diabetes. Nature 2001; 409:292–293.
86. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP,
Digby J, et al. Depot-related gene expression in human
subcutaneous and omental adipocytes. Diabetes
1998;47:1384–1391.
67. Adams M, Montague CT, Prins JB, Holder JC, Smith SA,
Sanders L, et al. Activators of peroxisome proliferator-acti-
vated receptor gamma have depot-specific effects on
human preadipocyte differentiation. Journal of Clinical
Investigation 1997; 100:3149–3153.
88. Despres J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A
& Bouchard C. Regional distribution of body fat, plasma
lipoproteins, and cardiovascular disease. Arteriosclerosis
1990; 10:497–511.
89. Pedersen SB, Jonler M & Richelsen B. Characterization of
regional and gender differences in glucocorticoid receptors
and lipoprotein lipase activity in human adipose tissue.
Journal of Clinical Endocrinology & Metabolism 1994;
78:1354–1359.
90. Fabris R, Nisoli E, Lombardi AM, Tonello C, Serra R,
Granzotto M, et al. Preferential channeling of energy fuels
toward fat rather than muscle during high free fatty acid
availability in rats. Diabetes 2001; 50:601–608.
91. Bjorntorp P. The regulation of adipose tissue distribution in
humans. International Journal of Obesity 1996;
20:291–302.
92. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer
G, Gertner J, et al. Assessment of growth hormone
dynamics in human immunodeficiency virus-related lipody-
strophy. Journal of Clinical Endocrinology & Metabolism
2001; 86:504–510.
93. Hadigan C, Corcoran C, Piecuch S, Rodriguez W &
Grinspoon S. Hyperandrogenemia in human
immunodeficiency virus-infected women with lipodys-
trophy syndrome. Journal of Clinical Endocrinology &
Metabolism 2000; 85:3544-3550.
94. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL
Jr , Cerundolo V, et al. An inhibitor of HIV-1 protease
modulates proteasome activity, antigen presentation, and T
cell responses. Proceedings of the National Academy of
Sciences, USA 1998; 95:13120–13124.
95. Nguyen AT, Gagnon A, Angel JB & Sorisky A. Ritonavir
increases the level of active ADD-1/SREBP-1 protein during
adipogenesis. AIDS 2000; 14:2467–2473.
96. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum C &
Hui DY. HIV protease inhibitor therapy increases hepatic
lipoprotein production via stabilisation of activated Sterol
Regulatory Element-Binding Protein-1 (SREBP-1) in the
nucleus. 8th Conference on Retroviruses and Opportunistic
Infections, 4–8 February 2001, Chicago, Ill., USA, Abstract
659.
Antiviral Therapy 6:3 159
Antiviralretoviral therapy and the lipodystrophy syndrome97. Schutt M, Meier M, Meyer M, Klein J, Aries SP & Klein
HH. The HIV-1 protease inhibitor indinavir impairs insulin
signalling in HepG2 hepatoma cells. Diabetologia 2000;
43:1145–1148.
98. Nolte LA, Yarasheski KE, Kawanaka K & Holloszy JO.
The HIV protease inhibitor indinavir decreases insulin- and
contraction-stimulated glucose transport in skeletal muscle.
Diabetes 2001; 50:1397–1401.
99. Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E,
Barbatelli G & Cinti S. Multilocular fat cells in WAT of
CL-316243-treated rats derive directly from white
adipocytes. American Journal of Physiology-Cell
Physiology 2000; 279:C670–C681.
100.Himms-Hagen J & Harper M-E. Physiological role of
UCP3 may be export of fatty acids from mitochondria
when fatty acid oxidation predominates: an hypothesis.
Experimental Biology and Medicine 2001; 226:78–84.
101.Nolan D & Mallal S. Getting to the HAART of insulin
resistance. AIDS 2001[in press].
102.Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH,
Gourley PJ, Stamm ER, et al. Fat distribution and meta-
bolic changes are strongly correlated and energy
expenditure is increased in the HIV lipodystrophy
syndrome. AIDS 2001[in press].
103.Shevitz AH, Knox TA, Spiegelman D, Roubenoff R,
Gorbach SL & Skolnik PR. Elevated resting energy expen-
diture among HIV-seropositive persons receiving highly
active antiretroviral therapy. AIDS 1999; 13:1351–1357.
104.Hobbs GA, Keilbaugh SA, Rief PM, Simpson MV. Cellular
targets of 3′ -azido-3′ -deoxythymidine: an early (non-
delayed) effect on oxidative phosphorylation. Biochemical
Pharmacology 1995; 50:381–390.
105.Barile M, Valenti D, Quagliarello E & Passarella S.
Mitochondria as cell targets of AZT (zidovudine). General
Pharmacology 1998; 31:531–538.
106.Masini A, Scotti C, Calligaro A, Cazzalini O, Stivala LA,
Bianchi L, et al. Zidovudine-induced experimental
myopathy: dual mechanism of mitochondrial damage.
Journal of the Neurological Sciences 1999; 166:131–140.
107.Das K, Lewis RY, Combatsiaris TP, Lin Y, Shapiro L,
Charrion MJ, et al. Predominant expression of the mito-
chondrial dicarboxylate carrier in white adipose tissue.
Biochemical Journal 1999; 344:313–320.
108.Nolan D, John M & Mallal S. Effects of gender and race
in the antiretroviral therapy associated lipodystrophy
syndrome. Journal of HIV Therapy 2001; 6:32–36.
109.Vonkeman HE, ten Napel CHH & van Oeveren-Dybicz
AM, Vermes I. β 3-adrenergic receptor polymorphism and
the antiretroviral therapy-related lipodystrophy syndrome.
AIDS 2000; 14:1463–1464.
110.Maher B, Alfirevic A, Vilar J, Wilkins E, Park BK &
Pirmohamed M. TNF-α promoter region polymorphisms in
patients with HIV-1 associated lipodystrophy. XIIIth
International AIDS Conference. Durban, South Africa,
2000, Abstract LB 113.
111.Hotamisligil GS. The role of TNFα and TNF receptors in
obesity and insulin resistance. Journal of Internal Medicine
1999; 245:621–625.
D Nolan et al.
©2001 International Medical Press 160
Received 15 December 2000; accepted 20 June 2001